Literature DB >> 7519757

Myelin basic protein in the cerebrospinal fluid of patients with brain tumors.

H Nakagawa1, M Yamada, T Kanayama, K Tsuruzono, Y Miyawaki, K Tokiyoshi, Y Hagiwara, T Hayakawa.   

Abstract

We measured the level of myelin basic protein (MBP) in the cerebrospinal fluid (CSF) of patients with various kinds of tumors, including malignant tumors, using radioimmunoassay. The CSF had been obtained by lumbar puncture through an Ommaya reservoir or a shunt device placed in the lateral ventricle. The level of MBP was high (> 4 ng/ml) in the patients with meningeal dissemination of malignant tumors, but in those who showed a good response to chemotherapy and/or radiation, it decreased or returned to the normal level, with improvement on the computed tomography and magnetic resonance imaging, cytological, general CSF, and neurological findings. Of seven malignant gliomas without CSF dissemination, six showed an elevated level of MBP before selective intra-arterial chemotherapy with a combination of etoposide and cisplatin administered via a microcatheter placed at A1, M1, P1-P2, and the basilar top. All CSF specimens obtained during the period of the intra-arterial chemotherapy showed an abnormally high (> 4 ng/ml) level of MBP that exceeded the prechemotherapy level. The MBP level decreased or returned to normal in the patients with a good response to chemotherapy after intra-arterial chemotherapy. In some patients with multiple metastatic brain tumors, the MBP level was elevated before treatment and returned to normal after treatment (surgical removal, chemotherapy, and/or irradiation) in all except one. Thus, there was a clear correlation between the timing of treatment and changes in imaging studies and MBP levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519757     DOI: 10.1227/00006123-199405000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

Review 2.  In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis.

Authors:  R J van Oostenbrugge; A H Hopman; F C Ramaekers; A Twijnstra
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

Review 3.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

Review 4.  Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke.

Authors:  Pierre Lescuyer; Laure Allard; Denis F Hochstrasser; Jean-Charles Sanchez
Journal:  Mol Diagn       Date:  2005

5.  Intraoperative values of S-100 protein, myelin basic protein, lactate, and albumin in the CSF and serum of neurosurgical patients.

Authors:  J de Vries; W A Thijssen; S E Snels; T Menovsky; N G Peer; K J Lamers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

6.  Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells.

Authors:  Hidemitsu Nakagawa; Satoru Sasagawa; Kazuyuki Itoh
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

7.  Serum myelin basic protein as a marker of brain injury in aneurysmal subarachnoid haemorrhage.

Authors:  Norbert Wąsik; Bartosz Sokół; Marcin Hołysz; Witold Mańko; Robert Juszkat; Piotr Paweł Jagodziński; Roman Jankowski
Journal:  Acta Neurochir (Wien)       Date:  2020-01-08       Impact factor: 2.216

8.  High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis.

Authors:  Xiaobin Luo; Shangyi Xu; Yali Zhong; Tianqi Tu; Youlin Xu; Xianglong Li; Bin Wang; Fubing Yang
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.